CLINICAL TRIAL SUMMARY

MDACC Study No:2010-0733 (clinicaltrials.gov NCT No: NCT01301807)
Title:Phase 1/1b Study of the efficacy and safety of the combination of Panobinostat + Carfilzomib in patients with relapsed/refractory myeloma
Principal Investigator:Jatin J. Shah
Treatment Agent:Carfilzomib; Panobinostat
Study Status:Open
Study Description:The goal of this clinical research study is to find the highest tolerable dose
levels of carfilzomib and LBH589 (panobinostat) that can be given in
combination to patients with myeloma. The safety of this drug combination will
also be studied.

Hide details for General InformationGeneral Information

Disease Group:Myeloma
Phase of Study:Phase I
Treatment Agents:Carfilzomib
Panobinostat
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Novartis
Onyx Therapeutics, Inc.
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jatin J. Shah
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-745-6130
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults